immune checkpoint inhibition

Atezolizumab - Avelumab - Durvalumab - Durvalumab + tremelimumab - Ipilimumab - Nivolumab - Pembrolizumab      

Select            
Trial Studied trt Control trt patientstagsROB Trial resultprogression or death (progression free survival PFS) death (overall survival)

gastric or gastro-oesophageal junction cancer (advanced)

nivolumab
ATTRACTION-2, 2017      NCTnivolumabplaceboLow risk of bias suggesting-37%
pembrolizumab
KEYNOTE-059 single-arm      NCTpembrolizumabnil -
Keynote 061, 2018    NCTpembrolizumabpaclitaxel2L 2nd line PD-L1 positive Risk of bias negative 27%-18%

Head and neck cancer

nivolumab
Checkmate-141, 2016      NCTnivolumabstandard treatment2L 2nd line platinum failure Risk of bias conclusive-11%-30%
pembrolizumab
KEYNOTE-040    NCTpembrolizumabstandard treatment2L 2nd line Risk of bias suggesting-19%

lung cancer (metastatic)

atezolizumab
IMpower150 (WT), 2018      NCTatezolizumab + bevacizumabbevacizumab (on top platinum-based CT)1L 1st line nonsquamous NSCLC Risk of bias suggesting-38%
IMpower150 (Teff), 2018        NCTatezolizumab + bevacizumabbevacizumab (on top platinum-based CT)1L, Teff 1st line nonsquamous NSCLC Risk of bias suggesting-49%
POPLAR Phase 2 atezolizumab, 2016    NCTatezolizumabdocetaxel2L 2nd+ line platinum failure Risk of bias negative-27%
OAK, 2016      NCTatezolizumabdocetaxel2L 2nd+ line platinum failure Risk of bias suggesting-5%-27%
durvalumab
PACIFIC, 2017      NCTdurvalumabplacebomaintenance maintenance therapy Low risk of bias conclusive-48%
ARCTIC PD-L1 negative, 2018    NCTdurvalumab + tremelimumabStandard of Care3L, PD-L1 negative -
ipilimumab
Reck, 2016      NCTipilimumab + chemotherapyplacebo + chemotherapySCLCLow risk of bias -
Govindan, 2017      NCTipilimumab + chemotherapyplacebo + chemotherapy1LLow risk of bias negative-9%
phase 2 (phased ipilimumab), 2012     ipilimumab + chemotherapyplacebo + chemotherapyLow risk of bias -
nivolumab
CheckMate 057, 2015      NCTnivolumabdocetaxel2L, non squamous 2nd+ line nonsquamous NSCLC Risk of bias suggesting-8%-27%
CheckMate 017, 2015    NCTnivolumabdocetaxel2L, squamous 2nd+ line squamous NSCLC Risk of bias suggesting-38%-41%
CheckMate 026, 2016    NCTnivolumabplatinum-based CT1L, PDL1 positive 1st line PD-L1 positive Risk of bias negative15%2%
CheckMate 227 (nivolumab + CT), 2018    NCTnivolumab + CTplatinum-based CT1L, PDL1 negatif 1st line PD-L1 negatif suggesting-26%
CheckMate 227 (High Tumor Mutational Burden), 2018      NCTnivolumab + ipilimumabplatinum-based CT1L, hi TMB 1st line Risk of bias suggesting-42%
pembrolizumab
Keynote 010 10mg, 2015      NCTpembrolizumab 10mgdocetaxel2L, PD-L1 positive 2nd+ line Risk of bias suggesting-21%-39%
Keynote 010 2mg, 2015      NCTpembrolizumab 2mgdocetaxel2L, PD-L1 positive 2nd+ line Risk of bias suggesting-12%-29%
Keynote 042 (>=1%), 2018    NCTpembrolizumabplatinum-based CT1L, PDL1 positive 1st line PD-L1 positive Risk of bias suggesting-19%
Keynote 024, 2015      NCTpembrolizumabplatinum-based CT1L, PDL1 positive 1st line PD-L1 positive Risk of bias suggesting-50%-40%
Keynote 042 (>=50%), 2018    NCTpembrolizumabplatinum-based CT1L, PDL1 positive 1st line PD-L1 positive Risk of bias suggesting-31%
Keynote 042 (>=20%), 2018    NCTpembrolizumabplatinum-based CT1L, PDL1 positive 1st line PD-L1 positive Risk of bias suggesting-23%
KEYNOTE-021 phase 2, 2016      NCTpembrolizumab + platinum-based CTplatinum-based CT1L nonsquamous 1st line nonsquamous NSCLC Exploratory suggesting-47%-46%
Keynote 189, 2018      NCTpembrolizumab + platinum-based CTplatinum-based CT1L PD-L1 positive nonsquamous 1st line nonsquamous NSCLC Low risk of bias conclusive-48%-51%
Keynote 407, 2018      NCTpembrolizumanb + CTplatinum-based CT1L squamous squamous NSCLC Risk of bias suggesting-36%

melanoma

ipilimumab
Robert, 2011      NCTipilimumab + dacarbazinedacarbazine1L 1st line Low risk of bias conclusive-28%
Hodi (ipi + gp100), 2010      NCTipi + gp100gp1002L 2nd line Risk of bias suggesting-31%
Hodi (ipi alone), 2010      NCTipilimumab 3 mg/kggp1002L 2nd line Risk of bias suggesting-36%
EORTC 18071 (Eggermont), 2015        NCTipilimumabplaceboadjuvant adjuvant Low risk of bias conclusive -24%-28%
nivolumab
CheckMate 037 (Weber), 2015      NCTnivolumabchemotherapy2L, anti-CTLA-4 failure 2nd line Risk of bias suggesting
CheckMate 066 (Robert), 2015      NCTnivolumabdacarbazine1L 1st line Low risk of bias conclusive -57%-58%
CheckMate 238, 2017      NCTnivolumabipilimumabadjuvant adjuvant Low risk of bias conclusive-35%
CheckMate 067 (nivo vs ipi), 2015      NCTnivolumabipilimumab1L 1st line Low risk of bias conclusive-43%
CheckMate 067 (nivo + ipi vs ipi), 2015    NCTnivolumab + ipilimumabipilimumab1L 1st line Low risk of bias conclusive -58%
Postow, 2015      NCTnivolumab + ipilimumabipilimumab1L 1st line Exploratory -
CheckMate 067 (nivo + ipi vs nivo), 2015      NCTnivolumab + ipilimumabnivolumab1L 1st line Exploratory -
pembrolizumab
KEYNOTE 002 (10mg/kg Q3W), 2015      NCTpembrolizumab 10mg/kgchemotherapy2L 2nd line Exploratory suggesting-50%
KEYNOTE 002 (2mg/kg Q3W), 2015      NCTpembrolizumab 2mg/kgchemotherapy2L 2nd line Exploratory suggesting -43%
KEYNOTE-006 (every 2W), 2015      NCTpembrolizumab (every 2W)ipilimumab1L 1st line Risk of bias suggesting -42%-32%
KEYNOTE-006 (every 3W), 2015      NCTpembrolizumab (every 3W)ipilimumab1L 1st line Risk of bias suggesting -42%-32%
KEYNOTE-001, 2014      NCTpembrolizumab 2mg/kgpembrolizumab 10mg/kg2L 2nd line Exploratory negative-16%9%
KEYNOTE-054, 2018      NCTpembrolizumabplaceboadjuvant adjuvant Low risk of bias conclusive -43%

multiple myeloma

pembrolizumab
KEYNOTE-185, 2018    NCTpembrolizumab, lenalidomide, dexametahsonelenalidomide, dexamethasonenot eligible for ASCTRisk of bias remark
KEYNOTE-183, 2018    NCTpembrolizumab + pomadoline + dexamethasonepomadoline + dexamethasonerrMMRisk of bias negative

renal-cell carcinoma (advanced)

nivolumab
Chekmate 025 (Motzer), 2015      NCTnivolumabeverolimus2LRisk of bias suggesting-12%-27%
CheckMate-214, 2017      NCTnivolumab + ipilimumabsunitinib1LRisk of bias conclusive-18%-32%

urothelial carcinoma (advanced)

atezolizumab
IMvigor211 (IC2/3)      NCTatezolizumabchemotherapy2nd line, IC2/3 2nd line Risk of bias suggesting-13%
IMVIGOR-130 (monotherapy)    NCTatezolizumabcontrolfirst line 1st line Risk of bias remark
IMvigor210 single-arm      NCTatezolizumabnil1st and 2nd line 1st line 2nd line Exploratory -
durvalumab
durvalumab phase 1/2 single-arm   durvalumabnil2nd line 2nd line Exploratory -
nivolumab
Checkmate 275 single-arm      NCTnivolumabnil2nd line 2nd line Exploratory -
pembrolizumab
KEYNOTE-052, 2017 single-arm      NCTpembrolizumab 1st line Risk of bias -
KEYNOTE-045, 2017    NCTpembrolizumabchemotherapy2nd line 2nd line Risk of bias suggesting-2%-27%
Keynote 361 monotherapy    NCTpembrolizumabchemotherapyfirst lineremark